<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerging Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28820136</article-id><article-id pub-id-type="pmc">5572891</article-id><article-id pub-id-type="publisher-id">16-1948</article-id><article-id pub-id-type="doi">10.3201/eid2309.161948</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Protective Effect of Val129-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease</subject></subj-group></article-categories><title-group><article-title>Protective Effect of Val<sub>129</sub>-PrP against Bovine Spongiform Encephalopathy but not Variant Creutzfeldt-Jakob Disease</article-title><alt-title alt-title-type="running-head">Val<sub>129</sub>-PrP and BSE, vCJD</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fern&#x000e1;ndez-Borges</surname><given-names>Natalia</given-names></name><xref ref-type="fn" rid="FN1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Espinosa</surname><given-names>Juan Carlos</given-names></name><xref ref-type="fn" rid="FN1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mar&#x000ed;n-Moreno</surname><given-names>Alba</given-names></name></contrib><contrib contrib-type="author"><name><surname>Aguilar-Calvo</surname><given-names>Patricia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Asante</surname><given-names>Emmanuel A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kitamoto</surname><given-names>Tetsuyuki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mohri</surname><given-names>Shirou</given-names></name></contrib><contrib contrib-type="author"><name><surname>Andr&#x000e9;oletti</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Torres</surname><given-names>Juan Mar&#x000ed;a</given-names></name></contrib><aff id="aff1">Centro de Investigaci&#x000f3;n en Sanidad Animal, Instituto Nacional de Investigaci&#x000f3;n y Tecnolog&#x000ed;a Agraria y Alimentaria (CISA-INIA); </aff><aff id="aff2">Valdeolmos, Madrid, Spain (N. Fern&#x000e1;ndez-Borges, J.C. Espinosa, A. Mar&#x000ed;n-Moreno, P. Aguilar-Calvo, J.M. Torres); </aff><aff id="aff3">MRC Prion Unit, Department of Neurodegenerative Disease, University College London, Institute of Neurology, London, UK (E.A. Asante); </aff><aff id="aff4">Tohoku University Graduate School of Medicine, Sendai, Japan (T. Kitamoto, S. Mohri); </aff><aff id="aff5">UMR INRA ENVT 1225, Interactions H&#x000f4;tes Agents Pathog&#x000e8;nes, Ecole Nationale V&#x000e9;t&#x000e9;rinaire de Toulouse, Toulouse, France (O. Andr&#x000e9;oletti)</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Juan Maria Torres Trillo, Centro de Investigaci&#x000f3;n en Sanidad Animal (CISA-INIA). 28130 Valdeolmos, Madrid, Spain; email: <email xlink:href="jmtorres@inia.es">jmtorres@inia.es</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><volume>23</volume><issue>9</issue><fpage>1522</fpage><lpage>1530</lpage><abstract><p>Bovine spongiform encephalopathy (BSE) is the only known zoonotic prion that causes variant Creutzfeldt-Jakob disease (vCJD) in humans. The major risk determinant for this disease is the polymorphic codon 129 of the human prion protein (Hu-PrP), where either methionine (Met<sub>129</sub>) or valine (Val<sub>129</sub>) can be encoded. To date, all clinical and neuropathologically confirmed vCJD cases have been Met<sub>129</sub> homozygous, with the exception of 1 recently reported Met/Val heterozygous case. Here, we found that transgenic mice homozygous for Val<sub>129</sub> Hu-PrP show severely restricted propagation of the BSE prion strain, but this constraint can be partially overcome by adaptation of the BSE agent to the Met<sub>129</sub> Hu-PrP. In addition, the transmission of vCJD to transgenic mice homozygous for Val<sub>129</sub> Hu-PrP resulted in a prion with distinct strain features. These observations may indicate increased risk for vCJD secondary transmission in Val<sub>129</sub> Hu-PrP&#x02013;positive humans with the emergence of new strain features.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Bovine spongiform encephalopathy</kwd><kwd>BSE</kwd><kwd>prion susceptibility</kwd><kwd>PrP</kwd><kwd>Val129-PrP</kwd><kwd>transmission barrier</kwd><kwd>variant Creutzfeldt-Jakob disease</kwd><kwd>vCJD</kwd><kwd>zoonoses</kwd><kwd>PRNP</kwd><kwd>methionine</kwd><kwd>valine</kwd><kwd>Met/Val</kwd><kwd>zoonoses</kwd><kwd>transmissible spongiform encephalopathies</kwd><kwd>ruminant</kwd><kwd>prions</kwd></kwd-group></article-meta></front><body><p>The presence of variant Creutzfeldt-Jakob disease (vCJD) is considered by strong epidemiologic, pathologic, and molecular evidence to be a likely consequence of human dietary exposure to the bovine spongiform encephalopathy (BSE) agent (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>&#x02013;<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>). Secondary vCJD infection has occurred through iatrogenic routes such as blood transfusion (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>&#x02013;<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). The pathogenesis of these fatal transmissible spongiform encephalopathies (TSEs), called prion diseases, is associated with the accumulation of the abnormal isoform (PrP<sup>Sc</sup>) of prion protein (PrP), which is converted from the normal cellular isoform (PrP<sup>C</sup>) (<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). This conversion process involves a posttranslational conformational change of PrP<sup>C</sup> and PrP<sup>Sc</sup> that can be distinguished biochemically from PrP<sup>C</sup> by its partial resistance to proteolysis and detergent insolubility (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>,<xref rid="R10" ref-type="bibr"><italic>10</italic></xref>).</p><p>The neuropathological features of vCJD are characterized by the presence of abundant florid PrP plaques and the propagation of type 4 disease-related PrP<sup>Sc</sup> in the brain (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R11" ref-type="bibr"><italic>11</italic></xref>). Differences in the level of glycosylation, as well as in the size of protease-digested PrP<sup>Sc</sup>, are widely used as surrogates of prion strain typing; 2 main classifications are recognized in the prion field (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). According to 1 of these classifications (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R13" ref-type="bibr"><italic>13</italic></xref>), type 4 PrP<sup>Sc</sup> is characterized by a fragment size and glycoform ratio similar to that seen in BSE and BSE transmitted to several other species, with a predominance of the diglycosylated PrP glycoform (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R13" ref-type="bibr"><italic>13</italic></xref>&#x02013;<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>).</p><p>Polymorphism at codon 129 of the human PrP gene (<italic>PRNP</italic>), where methionine (Met) or valine (Val) can be encoded, strongly affects susceptibility to human prion diseases (<xref rid="R16" ref-type="bibr"><italic>16</italic></xref>&#x02013;<xref rid="R20" ref-type="bibr"><italic>20</italic></xref>). vCJD has only been neuropathologically confirmed in persons homozygous for Met at residue 129 of human PrP (<xref rid="R21" ref-type="bibr"><italic>21</italic></xref>), with 1 exception of heterozygosity (Met/Val) at this codon (<xref rid="R22" ref-type="bibr"><italic>22</italic></xref>). In addition, asymptomatic peripheral involvement in vCJD infection has been reported in 2 Met/Val<sub>129</sub>&#x02013;positive persons (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>). Retrospective studies of the prevalence of subclinical vCJD infection using appendectomy and tonsillectomy specimens in the United Kingdom described 6 appendixes that were positive for disease-associated prion protein in Val/Val<sub>129</sub> persons (<xref rid="R23" ref-type="bibr"><italic>23</italic></xref>&#x02013;<xref rid="R25" ref-type="bibr"><italic>25</italic></xref>). All of these human studies, in addition to the extremely prolonged and variable incubation periods seen in prion transmission experiments when crossing a species barrier, suggest that persons encoding any of the 3 human PrP codon 129 genotypes may be susceptible to vCJD, including secondary vCJD transmitted through blood transfusion, blood products, tissue and organ transplantation, and other iatrogenic routes.</p><p>Because only 1 definite case of heterozygous Met/Val<sub>129</sub> vCJD and no homozygous Val<sub>129</sub> cases have been described, it is unknown whether the clinicopathologic characteristics and biochemical properties of vCJD would appear in persons with these codon 129 genotypes. To gain insights into that question, vCJD/BSE transmission studies in which either humanized overexpressing or knock-in transgenic mice were used have been performed (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>&#x02013;<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). However, some discrepancies in the transmission efficiency of vCJD to humanized knock-in transgenic mice can be found, depending on the origin of the mice and on the vCJD isolate (<xref rid="R29" ref-type="bibr"><italic>29</italic></xref>,<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>). Previous studies in humanized overexpressing transgenic mice revealed that the 3 human PrP codon 129 genotypes can be infected with vCJD but show significant differences depending on the genotype. Moreover, mice with the Val/Val<sub>129</sub> genotype were more susceptible to vCJD infection than expected but lack the neuropathological characteristics observed with Met/Met<sub>129</sub> (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>&#x02013;<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>).</p><p>In this study, we evaluated the zoonotic potential of BSE and BSE adapted to different species by using transgenic mice overexpressing similar levels of human PrP<sup>C</sup> carrying Met/Met, Met/Val, or Val/Val at position 129 of human PrP. Furthermore, we used these models to re-evaluate the potential for human-to-human spread of vCJD, as well as the differential susceptibility and characteristics of the transmitted disease across the different <italic>PRNP</italic> codon 129 genotypes in humans.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Ethics Statement</title><p>We carried out animal experiments in strict accordance with the recommendations in the guidelines of the Code for Methods and Welfare Considerations in Behavioral Research with Animals (Directive 86/609EC and 2010/63/EU), and all efforts were made to minimize suffering. Experiments were approved by the Committee on the Ethics of Animal Experiments of the Instituto Nacional de Investigaci&#x000f3;n y Tecnolog&#x000ed;a Agraria y Alimentaria (Madrid, Spain; permit nos. CEEA2012/024 and CEEA2009/004).</p></sec><sec><title>TSE Isolates</title><p>We used 11 isolates from different sources in this study (<xref ref-type="table" rid="T1">Table 1</xref> [<xref rid="R31" ref-type="bibr"><italic>31</italic></xref><italic>&#x02013;</italic><xref rid="R39" ref-type="bibr"><italic>39</italic></xref>]). For mouse inoculation, we prepared all isolates from brain tissues as 10% weight/volume (wt/vol) homogenates in 5% glucose. We performed second passages by inoculating transgenic mice with 10% (wt/vol) homogenates in 5% glucose of brains selected from passage 1.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><title>Description of prion isolates used in analysis of bovine spongiform encephalopathy and Creutzfeldt-Jakob disease*</title></caption><table frame="hsides" rules="groups"><col width="89" span="1"/><col width="75" span="1"/><col width="244" span="1"/><col width="72" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Isolate</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Sample codification</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Description (reference)</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Supplier&#x02020;</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-sCJD MM1</td><td valign="top" align="center" rowspan="1" colspan="1">BC 1011</td><td valign="top" align="center" rowspan="1" colspan="1">sCJD PrP-Met<sub>129</sub> type 1 human natural case</td><td valign="top" align="center" rowspan="1" colspan="1">BHUFA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-sCJD VV2</td><td valign="top" align="center" rowspan="1" colspan="1">BC 1452</td><td valign="top" align="center" rowspan="1" colspan="1">sCJD PrP-Val<sub>129</sub> type 2 human natural case</td><td valign="top" align="center" rowspan="1" colspan="1">BHUFA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-TSE negative</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">TSE free human brain</td><td valign="top" align="center" rowspan="1" colspan="1">NIBSC</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>0</sub></td><td valign="top" align="center" rowspan="1" colspan="1">Fr (139)</td><td valign="top" align="center" rowspan="1" colspan="1">BSE naturally infected cow (<italic>31</italic>,<italic>32</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">INRA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>2</sub></td><td valign="top" align="center" rowspan="1" colspan="1">UK (PG1199/00)</td><td valign="top" align="center" rowspan="1" colspan="1">BSE naturally infected cow (<italic>33</italic>,<italic>34</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">VLA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>0</sub>/TgPo</td><td valign="top" align="center" rowspan="1" colspan="1">Ca-BSE<sub>0</sub>/Tg001</td><td valign="top" align="center" rowspan="1" colspan="1">BSE transmitted experimentally to porcine transgenic mice (<italic>32</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">CISA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>0</sub>/Sh(ARQ)</td><td valign="top" align="center" rowspan="1" colspan="1">Fr (ARQ0)</td><td valign="top" align="center" rowspan="1" colspan="1">Pool of brains from terminally ill ARQ/ARQ sheep inoculated with Ca-BSE (<italic>31</italic>,<italic>32</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">INRA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/Go</td><td valign="top" align="center" rowspan="1" colspan="1">gBSE-P12</td><td valign="top" align="center" rowspan="1" colspan="1">Pool of brains from 3 terminally ill wild type goats inoculated with a mixture of 4 cattle-BSE field cases (<italic>35</italic>&#x02013;<italic>37</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">Roslin</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Go-BSE</td><td valign="top" align="center" rowspan="1" colspan="1">Fr (CH636)</td><td valign="top" align="center" rowspan="1" colspan="1">Goat BSE case (<italic>38</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">AFSSA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>1</sub></td><td valign="top" align="center" rowspan="1" colspan="1">UK (NHBY/0014)</td><td valign="top" align="center" rowspan="1" colspan="1">vCJD PrP-Met<sub>129</sub> human infected case (<italic>39</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">NIBSC</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>2</sub></td><td valign="top" align="center" rowspan="1" colspan="1">BC 1458</td><td valign="top" align="center" rowspan="1" colspan="1">vCJD PrP-Met<sub>129</sub> human infected case</td><td valign="top" align="center" rowspan="1" colspan="1">BHUFA</td></tr></tbody></table><table-wrap-foot><p>*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met<sub>129</sub>, methionine; PrP, prion protein; sCJD, sporadic CJD; TSE, transmissible spongiform encephalopathy; Val<sub>129</sub>, valine; vCJD, variant CJD.&#x02028;&#x02020;AFSSA, Agence Fran&#x000e7;aise de S&#x000e9;curit&#x000e9; Sanitaire des Aliments National TSE Reference Laboratory, Lyon, France; BHUFA, Biobanco Hospital Universitario Fundaci&#x000f3;n Alcorc&#x000f3;n, Madrid, Spain; CISA, Centro de Investigaci&#x000f3;n en Sanidad Animal, Madrid, Spain; INRA, French National Institute for Agricultural Research, Nouzilly, France; NIBSC, National Institute for Biologic Standards and Control Creutzfeld-Jakob Disease Resource Centre, South Mimms, Potters Bar, United Kingdom; Roslin, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, United Kingdom; VLA, Veterinary Laboratory Agency, New Haw. Addlestone, Surrey, United Kingdom. </p></table-wrap-foot></table-wrap></sec><sec><title>Mouse Transmission Studies</title><p>We inoculated all isolates in 3 different transgenic mouse models: 1) HuPrP-Tg340-Met<sub>129</sub> (TgMet<sub>129</sub>) mouse line expressing human Met<sub>129</sub>-PrP<sup>C</sup> variant (<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>); 2) HuPrP-Tg361-Val<sub>129</sub> (TgVal<sub>129</sub>) mouse line expressing human Val<sub>129</sub>-PrP<sup>C</sup> variant (<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>); and 3) HuPrP-Tg351-Met/Val<sub>129</sub> (TgMet/Val<sub>129</sub>) transgenic mouse line obtained by mating TgMet<sub>129</sub> and TgVal<sub>129</sub> mice (<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>). All of these transgenic lines show similar brain expression levels of PrP<sup>C</sup> (around 4-fold the level of expression in the human brain) on a mouse PrP null background. We performed additional inoculations in HuPrP-Tg362-Val<sub>129</sub>, a transgenic mouse line expressing 8-fold the level of PrP<sup>C</sup> expression in human brain (TgVal<sub>129</sub> [8&#x000d7;]) (<xref rid="R41" ref-type="bibr"><italic>41</italic></xref>). We performed subsequent bioassays for the detection of low-level propagation of infectious BSE and BSE-derived prions in BoPrP-Tg110 mice, which are highly susceptible to vCJD prions (<xref rid="R42" ref-type="bibr"><italic>42</italic></xref>,<xref rid="R43" ref-type="bibr"><italic>43</italic></xref>), probably caused by the trace-back phenomenon (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p><p>We anesthetized individually identified mice, 6&#x02013;7 weeks of age, with isoflurane and inoculated them with a 2-mg equivalent of brain homogenate in the right parietal lobe by using a 25-gauge disposable hypodermic needle. We observed mice daily and assessed neurologic status 2 times per week. When progression of a TSE disease was evident or at the established experimental endpoint (700 days postinoculation [dpi]), we euthanized the animal for ethical reasons and performed necropsy, excising the brain. We then fixed part of the brain by immersion in neutral-buffered 10% formalin (4% 2-formaldehyde) and used the tissue for quantifying spongiform degeneration by histopathology. We froze the remaining tissue at &#x02212;20&#x000b0;C and used it to determine the presence of disease-associated proteinase K (PK)&#x02013;resistant PrP (PrP<sup>res</sup>) by Western blot. </p><p>In all cases, we calculated mouse survival time and disease attack rate for each isolate. We expressed survival times as mean &#x000b1;SD of the dpi for all mice positive for PrP<sup>res</sup>. We defined the attack rate as the proportion of all inoculated mice whose samples tested positive for PrP<sup>res</sup>. We used brain homogenates from PrP<sup>res</sup>&#x02013;positive mice, where available, for further passaging. When all mice were scored negative for PrP<sup>res</sup> on primary passage, we used PrP<sup>res</sup>-negative brain homogenates for second passage.</p></sec><sec><title>Western Blot</title><p>We homogenized frozen brain tissues (175 &#x000b1; 20 mg) in 5% glucose in distilled water in grinding tubes (Bio-Rad, Hercules, CA, USA) adjusted to 10% (wt/vol) by using a TeSeE Precess 48TM homogenizer (Bio-Rad), according to the manufacturer&#x02019;s instructions. We determined presence of PrP<sup>res</sup> in transgenic mouse brains by Western blot, using the reagents of the ELISA commercial test TeSeE (Bio-Rad). Based on a previously described protocol (<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>), we treated 10&#x02013;100 &#x003bc;L of 10% wt/vol brain homogenates with proteinase K; the resulting samples were loaded in 12% Bis-Tris Gel (Criterion XT; Bio-Rad). We transferred proteins electrophoretically onto PVDF membranes (Millipore, Billerica, MA, USA), which were blocked overnight with 2% BSA blocking buffer (Sigma-Aldrich, St. Louis, MO, USA). For immunoblotting, we incubated with Sha 31 (<xref rid="R44" ref-type="bibr"><italic>44</italic></xref>) monoclonal antibody (mAb) at a concentration of 1 &#x000b5;g/mL to identify the 145-WEDRYYRE-152 epitope of the human PrP<sup>C</sup> sequence. To detect immunocomplexes, we incubated the membranes for 1 h with horseradish peroxidase conjugated anti-mouse IgG (GE Healthcare Amersham Biosciences, Little Chalfont, UK). Immunoblots were developed with enhanced chemiluminiscence ECL Select (GE Healthcare Amersham Biosciences). Images were captured using the ChemiDoc WRS+ System (Bio-Rad) and processed using Image Lab 5.2.1 software (Bio-Rad).</p></sec><sec><title>Histopathological Analysis</title><p>We performed procedures for the histopathological analysis of mouse brains as previously described (<xref rid="R45" ref-type="bibr"><italic>45</italic></xref>). We immediately fixed mouse brain samples in neutral-buffered 10% formalin (4% 2-formaldehyde) during necropsy and embedded the tissues in paraffin later. After deparaffinization, we stained 2 &#x003bc;m&#x02013;thick tissue slices with hematoxylin and eosin and established lesion profiles by using published standard methods (<xref rid="R46" ref-type="bibr"><italic>46</italic></xref>). We conducted paraffin-embedded tissue (PET) blots as previously described (<xref rid="R47" ref-type="bibr"><italic>47</italic></xref>).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>BSE Resistance in TgVal<sub>129</sub> Mice </title><p>To evaluate the relative susceptibility of the 3 human <italic>PRNP</italic> codon 129 genotypes to BSE, we performed serial transmission studies in 3 transgenic mouse lines expressing human PrP. These mouse lines were homozygous for Met (TgMet<sub>129</sub>) or Val (TgVal<sub>129</sub>) at codon 129 of human PrP or were their F1 cross (TgMet/Val<sub>129</sub>). These mouse models expressed similar human PrP levels, &#x02248;4-fold more than that seen in uninfected human brain tissue (<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>). We observed no clinical signs of prion disease or PrP<sup>res</sup> accumulation in control mice inoculated with TSE-free control brain homogenate. The 3 human transgenic mouse models were readily infected when inoculated with sporadic CJD (sCJD) (<xref ref-type="table" rid="T2">Table 2</xref>). The 2 sCJD cases used as inocula in this study were classified as Met<sub>129</sub> type 1 (Hu-sCJD MM1) and Val<sub>129</sub> type 2 (Hu-sCJD VV2) (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>) on the basis of the patient&#x000b4;s <italic>PRNP</italic> genotype at codon 129 and the PrP<sup>res</sup> Western blot profiles of these samples.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><title>Transmission of cattle, porcine, sheep, and goat BSE isolates to mice in transgenic mouse lines TgMet129, TgMet/Val129, and TgVal129*</title></caption><table frame="hsides" rules="groups"><col width="76" span="1"/><col width="67" span="1"/><col width="65" span="1"/><col width="8" span="1"/><col width="61" span="1"/><col width="67" span="1"/><col width="9" span="1"/><col width="58" span="1"/><col width="68" span="1"/><thead><tr><th rowspan="3" valign="bottom" align="left" scope="col" colspan="1">Isolates<hr/></th><th valign="bottom" colspan="8" align="center" scope="colgroup" rowspan="1">Mean survival time, d &#x000b1;SD (no. PrP<sup>res</sup>-positive/inoculated animals) [reference]&#x02020;&#x02021;</th></tr></thead><tbody><tr><td valign="bottom" colspan="2" align="center" scope="row" rowspan="1">TgMet<sub>129</sub><hr/></td><td rowspan="2" valign="bottom" align="left" colspan="1"/><td valign="bottom" colspan="2" align="center" rowspan="1">TgMet/Val<sub>129</sub><hr/></td><td rowspan="2" valign="bottom" align="left" colspan="1"/><td valign="bottom" colspan="2" align="center" rowspan="1">TgVal<sub>129</sub><hr/></td></tr><tr><td valign="bottom" colspan="1" align="center" scope="row" rowspan="1">First passage<hr/></td><td valign="bottom" align="center" rowspan="1" colspan="1">Second passage<hr/></td><td valign="bottom" colspan="1" align="center" rowspan="1">First passage<hr/></td><td valign="bottom" align="center" rowspan="1" colspan="1">Second passage<hr/></td><td valign="bottom" colspan="1" align="center" rowspan="1">First passage<hr/></td><td valign="bottom" align="center" rowspan="1" colspan="1">Second passage<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-sCJD MM1</td><td valign="top" align="center" rowspan="1" colspan="1">219 &#x000b1;17 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">239 &#x000b1;8 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">243 &#x000b1;14 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">260 &#x000b1;13 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">327 &#x000b1;19 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">286 &#x000b1;16 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-sCJD VV2</td><td valign="top" align="center" rowspan="1" colspan="1">618 &#x000b1;81 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">509 &#x000b1;41 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">588 &#x000b1;74 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">594 &#x000b1;86 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">168 &#x000b1;12 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">169 &#x000b1;12 (6/6) [<xref rid="R40" ref-type="bibr"><italic>40</italic></xref>]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hu-TSE negative</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>0</sub></td><td valign="top" align="center" rowspan="1" colspan="1">739 (1/6) (<italic>31</italic>)</td><td valign="top" align="center" rowspan="1" colspan="1">633 &#x000b1;32 (6/6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>2</sub></td><td valign="top" align="center" rowspan="1" colspan="1">491&#x02013;707 (0/9) [<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">572 &#x000b1;37 (3/4) [<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/5)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/3)&#x000a7;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/3)&#x000a7;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/TgPo</td><td valign="top" align="center" rowspan="1" colspan="1">653 &#x000b1;45 (3/5)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/Sh(ARQ)</td><td valign="top" align="center" rowspan="1" colspan="1">615 &#x000b1;84 (4/6) [<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>]</td><td valign="top" align="center" rowspan="1" colspan="1">564 &#x000b1;39 (5/5) [<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>]</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700b (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/Go</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">476 (1/10)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/5)&#x000b6;</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Go-BSE</td><td valign="top" align="center" rowspan="1" colspan="1">683 &#x000b1; 36 (6/6)</td><td valign="top" align="center" rowspan="1" colspan="1">675 &#x000b1; 36 (5/5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)</td><td valign="top" align="center" rowspan="1" colspan="1">ND</td></tr></tbody></table><table-wrap-foot><p>*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met<sub>129</sub>, methionine; ND, not done; PrP<sup>res</sup>, proteinase K&#x02013;resistant PrP; sCJD, sporadic CJD; Val<sub>129</sub>, valine; vCJD, variant CJD. &#x02028;&#x02020;Survival time is indicated for all mice that scored positive for PrP<sup>res</sup>&#x02028;&#x02021;Animals without clinical signs were euthanized at 700 dpi.&#x02028;&#x000a7;Three additional animals were culled before the end of the experiment because of intercurrent illnesses; all were negative for brain PrP<sup>res</sup> by using Western blot.&#x02028;&#x000b6;Positive subclinical infection tested in Bo-Tg110 mice.</p></table-wrap-foot></table-wrap><p>We inoculated the 3 mouse models intracerebrally with a panel of BSE isolates from different species (cattle, pig, sheep, and goat; <xref ref-type="table" rid="T2">Table 2</xref>). As previously described in TgMet<sub>129</sub> mice (<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>), we found a higher transmission efficiency adjudged by comparatively higher attack rates for BSE isolates previously passaged in other species than for cattle BSE, suggesting a strong transmission barrier to cattle BSE in these mice.</p><p>At completion of the first and second passages, none of the TgVal<sub>129</sub> mice challenged with the different BSE isolates developed clinical disease, and no PrP<sup>res</sup> accumulation was found in their brains (<xref ref-type="table" rid="T2">Table 2</xref>). Because of intercurrent illnesses, the group of TgVal<sub>129</sub> mice challenged with Ca-BSE<sub>2</sub> was considerably reduced in size; however, the absence of transmission to TgVal<sub>129</sub> mice challenged with a second BSE inocula, Ca-BSE<sub>0</sub>, reinforces this negative result. In addition, results of subsequent passage of brain homogenates from these mice to BoPrP-Tg110 mice were negative, ruling out the presence of subclinical infection, with the exception of TgVal<sub>129</sub> mice inoculated with Go-BSE. For this isolate, 3 of 6 BoPrP-Tg110 mouse brains showed detectable PrP<sup>res</sup> and had a long incubation time of 427 &#x000b1; 38 dpi, suggesting very low infectivity (<xref ref-type="local-data" rid="SD1">Technical Appendix</xref> Table 1).</p><p>To confirm that the lack of susceptibility of TgVal<sub>129</sub> mice to cattle BSE and to BSE previously adapted in different species was not caused by inadequate PrP substrate, we used the TgVal<sub>129</sub> (8&#x000d7;) mouse line (<xref rid="R41" ref-type="bibr"><italic>41</italic></xref>). However, even under these high human PrP expression level conditions, none of the inoculated TgVal<sub>129</sub> (8&#x000d7;) mice showed any evidence of infection after challenge with the different BSE isolates (<xref ref-type="local-data" rid="SD1">Technical Appendix</xref> Table 2). This result indicates that even an increase in the TgVal<sub>129</sub> PrP expression level is not enough to allow transmission of BSE prions, irrespective of the species in which BSE has been previously passaged.</p><p>In a similar manner to that seen in the TgVal<sub>129</sub> mice, we observed no clinical disease and no disease-associated PK-resistant PrP accumulation on first or second passage of the different BSE isolates in TgMet/Val<sub>129</sub> mice. However, we did observe an exception in 1 TgMet/Val<sub>129</sub> mouse inoculated with Go-BSE without clinical signs but with a positive score for brain PrP<sup>res</sup> that died at 476 dpi (<xref ref-type="table" rid="T2">Table 2</xref>). These findings support the interpretation that human-PrP Val<sub>129</sub> polymorphism severely restricts propagation of the BSE prion strain independently of the species in which it had previously been adapted.</p></sec><sec><title>BSE Adaptation to the Human PrP Sequence</title><p>In parallel to the transmission experiments with the different BSE isolates, we also inoculated the 3 humanized transgenic mouse models with human brain material from 2 different cases of vCJD PrP-Met<sub>129</sub> (Hu-vCJD<sub>1</sub> and Hu-vCJD<sub>2</sub>). On first passage, 100% of the TgMet<sub>129</sub> mice developed clinical disease in response to all inocula in the panel (<xref ref-type="table" rid="T3">Table 3</xref>). However, only the inoculum Hu-vCJD<sub>2</sub> previously passaged in TgMet/Val<sub>129</sub> mice caused clinical disease in the same heterozygous genotype upon serial passages; the rest of the inocula caused only subclinical infections in this genotype (<xref ref-type="table" rid="T3">Table 3</xref>). </p><table-wrap id="T3" position="float"><label>Table 3</label><caption><title>Intracerebral inoculation of transgenic mice that express human PrP with vCJD and with vCJD previously adapted in TgMet129 or TgMet/Val129 mice*</title></caption><table frame="hsides" rules="groups"><col width="193" span="1"/><col width="99" span="1"/><col width="94" span="1"/><col width="94" span="1"/><thead><tr><th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Isolates<hr/></th><th valign="middle" colspan="3" align="center" scope="colgroup" rowspan="1">Mean survival time, d &#x000b1;SD (no. PrP<sup>res</sup>-positive/inoculated animals) [reference]&#x02020;</th></tr></thead><tbody><tr><td valign="middle" colspan="1" align="center" scope="row" rowspan="1">TgMet<sub>129</sub><hr/></td><td valign="middle" align="center" rowspan="1" colspan="1">TgMet/Val<sub>129</sub><hr/></td><td valign="middle" align="center" rowspan="1" colspan="1">TgVal<sub>129</sub><hr/></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>1</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">626 &#x000b1;29 (6/6) [<italic>31</italic>]</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (3/3)&#x000a7;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>1</sub>&#x02192;TgMet<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">650 &#x000b1;60 (4/4)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>2</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">545 &#x000b1;146 (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (0/6)#</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>2</sub>&#x02192;TgMet<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">564 &#x000b1;39 (4/4)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (2/2)&#x000b6;</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hu-vCJD<sub>2</sub>&#x02192;TgMet/Val<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">601 &#x000b1;32 (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">651 &#x000b1;17 (7/7)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (7/7)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE<sub>2</sub>&#x02192;TgMet<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">614 &#x000b1;87 (6/6)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (4/4)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (3/4)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/Sh(ARQ)&#x02192;TgMet<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">534 &#x000b1;55 (5/6)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/6)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (5/6)</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Ca-BSE/Go&#x02192;TgMet<sub>129</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">609 &#x000b1;67 (5/5)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (4/4)</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e;700&#x02021; (6/6)</td></tr></tbody></table><table-wrap-foot><p>*BSE, bovine spongiform encephalopathy; Ca, cattle; CJD, Creutzfeldt-Jakob disease; Go, goat; Hu, human; Met<sub>129</sub>, methionine; PrP, prion protein; PrP<sup>res</sup>, proteinase K&#x02013;resistant PrP; sCJD, sporadic CJD; Val<sub>129</sub>, valine; vCJD, variant CJD.&#x02028;&#x02020;Survival time is indicated for all mice scored positive for PrP<sup>res</sup>.&#x02028;&#x02021;Animals were euthanized without clinical signs at 700 dpi.&#x02028;&#x000a7;Three additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for brain PrP<sup>res</sup> on WB.&#x02028;&#x000b6;Four additional animals had to be culled before the end of the experiment because of intercurrent illnesses; all were negative for PrP<sup>res</sup> expression on Western blot.&#x02028;#Positive subclinical infection tested in Bo-Tg110 mice.</p></table-wrap-foot></table-wrap><p>The PrP<sup>res</sup> molecular profile (<xref ref-type="fig" rid="F1">Figure 1</xref>, panel A, lanes 2, 3, and 5; <xref ref-type="fig" rid="F1">Figure 1</xref>, panel B) and the PrP<sup>res</sup> distribution patterns on paraffin-embedded tissue (PET) blots in the mouse brains (<xref ref-type="fig" rid="F2">Figure 2</xref>, panels A, B, C) were similar in both the TgMet<sub>129</sub> and TgMet/Val<sub>129</sub> mice, with or without clinical disease. However, we consistently observed a lower PrP<sup>res</sup> accumulation in TgMet/Val<sub>129</sub> mice compared with TgMet homozygous animals, particularly in the hippocampus area, probably caused by a slower conversion rate of PrP<sup>Sc</sup> in these animals with a half dose of PrP-Met<sub>129</sub>.</p><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Biochemical features of the protease-resistant prion protein (PrPres) detected in the brain of TgMet129, TgMet/Val129, and TgVal129 mice inoculated with vCJD. A) PrPres detected in TgMet129 (lanes 2 and 5), TgMet/Val129 (lane 3), and TgVal129 (lanes 4 and 6) mice inoculated with vCJD brain homogenate or TgMet129-passaged vCJD prions. Similar quantities of PrPres were loaded for adequate comparison and immunoblots were detected with Sha31 monoclonal antibody (mAb). The original vCJD isolate (Hu-vCJD2) used for mouse inoculations was also included in the blot (lanes 1 and 7). sCJD VV2 and MM1 isolates were included for biochemical comparative purposes (lanes 8 and 9, respectively). Molecular weight (MW) in kDa is shown. B) Glycoform analysis of PrPres from TgMet129, TgMet/Val129 and TgVal129 mice inoculated with vCJD brain homogenate or TgMet129-passaged vCJD prions. PrPres was detected by Western blot testing using the Sha31 mAb, as for panel A. The data shown are the means of &#x0003e;4 measurements in &#x0003e;2 different Western blots using the Image Lab (Bio-Rad, Hercules, CA, USA) program after capture with ChemiDoc XRS+ (Bio-Rad) under nonsaturating conditions. Error bars indicate SD. CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; vCJD, variant CJD.</p></caption><graphic xlink:href="16-1948-F1"/></fig><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>Protease-resistant prion protein distribution pattern in brains of prion protein humanized transgenic mice inoculated with variant Creutzfeldt-Jakob disease (vCJD) on second passage. A, B) TgMet129 mice inoculated with vCJD. C) TgMet/Val129 mice inoculated with vCJD. D, E) TgVal129 mice inoculated with vCJD propagated in TgMet129 mice. Original magnification &#x000d7;20 for all panels.</p></caption><graphic xlink:href="16-1948-F2"/></fig><p>In sharp contrast, none of the TgVal<sub>129</sub> mice challenged with the 2 vCJD primary inocula, Hu-vCJD<sub>1</sub> and Hu-vCJD<sub>2</sub>, developed clinical disease and no PrP<sup>res</sup> accumulation was found in their brains after Western blot (WB) analysis (<xref ref-type="table" rid="T3">Table 3</xref>). However, subsequent passage of brain homogenates from TgVal<sub>129</sub> mice inoculated with Hu-vCJD<sub>2</sub> (that remained apparently uninfected) to BoPrP-Tg110 mice showed evidence of subclinical infection. These subpassages led to a mean incubation time of 371 &#x000b1; 5 dpi and to propagation of PrP<sup>res</sup> that was detectable by WB in 100% of animals (<xref ref-type="local-data" rid="SD1">Technical Appendix</xref> Table 1), showing a biochemical pattern indistinguishable from that of cattle BSE infection in this mouse model.</p><p>These results suggest that the adaptation of the BSE agent to human PrP sequence could favor its transmission to the polymorphic human PrP Val<sub>129</sub> genotype. In this context, we passaged all isolates in TgMet<sub>129</sub> mice before subsequent inoculation in TgVal<sub>129</sub> mice. Although we did not observe clinical prion disease, the inoculated TgVal<sub>129</sub> mice had an infection rate remarkably close to 100%, as assessed by the presence of brain PrP<sup>res</sup> at the end of the experiment (<xref ref-type="table" rid="T3">Table 3</xref>). We obtained similar results with the Hu-vCJD<sub>2</sub> isolate after 1 passage in TgMet/Val<sub>129</sub> mice and subsequent inoculation into TgVal<sub>129</sub> mice (<xref ref-type="table" rid="T3">Table 3</xref>). These observations support the hypothesis that adaptation of BSE agent to the human-PrP Met<sub>129</sub> amino-acid sequence promotes its transmission to human PrP Val<sub>129</sub>&#x02013;expressing hosts.</p></sec><sec><title>vCJD Prions in TgVal<sub>129</sub> Mice </title><p>Challenge of TgMet<sub>129</sub> or TgMet/Val<sub>129</sub> mice with vCJD prions resulted in faithful propagation of a typical PrP<sup>vCJD</sup> (also named type 4), characterized by low size fragments (19-kDa fragment for the aglycosyl band) and prominent diglycosylated species on WB (<xref ref-type="fig" rid="F1">Figure 1</xref>, panel A, lanes 2, 3). These biochemical properties were accompanied by the key neuropathological hallmark of vCJD, the presence of abundant florid PrP plaques determined by immunohistochemical analysis of the brain (<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>) (data not shown).</p><p>In contrast, TgMet<sub>129</sub>&#x02013;passaged vCJD-inoculated TgVal<sub>129</sub> mice propagated a PrP<sup>Sc</sup> with a WB signature that shared the same predominance of the diglycosylated glycoform seen in type 4 PrP<sup>Sc</sup> but was distinguished by PK digestion products of greater molecular mass (<xref ref-type="fig" rid="F1">Figure 1</xref>, panel A, lanes 4, 6), which closely resemble those seen in human type 2 PrP<sup>Sc</sup> (<xref ref-type="fig" rid="F1">Figure 1</xref>, panel A, lane 8). This differential biochemical pattern is associated with the presence of amyloid plaques restricted to the corpus callosum without a florid morphology. Moreover, we saw no specific vacuolar changes in the brains of these animals. PET blot analysis of these brains confirmed PrP<sup>Sc</sup> deposition in corpus callosum and head of caudate nucleus in the brain of vCJD-inoculated TgVal<sub>129</sub> mice (<xref ref-type="fig" rid="F2">Figure 2</xref>, panels D, E). However, PrP<sup>Sc</sup> deposition was quite limited in comparison with those observed in vCJD-inoculated TgMet<sub>129</sub> (<xref ref-type="fig" rid="F2">Figure 2</xref>, panels A, B) and TgMet/Val<sub>129</sub> mice (<xref ref-type="fig" rid="F2">Figure 2</xref>, panel C).</p><p>These results resemble those previously described in a different TgVal<sub>129</sub> mouse line in which neuropathological and molecular features similar to those observed in our TgVal<sub>129</sub> were characterized (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>,<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>). To prove the same PrP<sup>res</sup> molecular profile identity between this previously characterized PrP<sup>Sc</sup> (called type 5 PrP<sup>Sc</sup>, vCJD<bold>&#x02192;</bold>129VV Tg152c) and our vCJD-TgVal<sub>129</sub> PrP<sup>Sc</sup>, we performed a biochemical characterization by WB and found no molecular profile differences in PrP<sup>res</sup> from the various mouse lines (<xref ref-type="fig" rid="F3">Figure 3</xref>, lanes 6 and 7). These particular molecular mass and glycoform profile characteristics seem to be a hallmark of vCJD transmission to human-PrP Val<sub>129</sub>, since these features were also found in a different human-PrP Val<sub>129</sub> transgenic mouse line challenged with vCJD (vCJD<bold>&#x02192;</bold>Ki-Hu129V/V) (<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>) (<xref ref-type="fig" rid="F3">Figure 3</xref>, lane 8). These results, suggesting vCJD prion infection can result in the generation of distinct molecular and neuropathological phenotypes dependent on human-PrP polymorphic residue 129, are in accordance with those reported previously (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>,<xref rid="R46" ref-type="bibr"><italic>46</italic></xref>).</p><fig id="F3" fig-type="figure" position="float"><label>Figure 3</label><caption><p>Biochemical comparison of brain protease-resistant prion protein (PrPres) detected in transgenic mice expressing prion protein Met129, and Val129 mice and inoculated with vCJD brain homogenate. Similar quantities of PrPres were loaded for adequate comparison, and immunoblots were detected by using Sha31 monoclonal antibody. Lanes 4 and 6 show passages from this study; lane 5 shows sample codification I-10629 and lane 7 sample codification I-11724 from the MRC Prion Unit in the United Kingdom (<xref rid="R27" ref-type="bibr">27</xref>); lane 8 shows sample codification #139-A5603 from Tohoku University Graduate School of Medicine, Sendai, Japan (<xref rid="R30" ref-type="bibr">30</xref>). The original vCJD isolate (Hu-vCJD2) used for mouse inoculations in this study was also included on the blot (lanes 3 and 9); sCJD MM1 (lane 1) and VV2 (lane 2) isolates were included for biochemical comparative purposes. Molecular weight (MW) in kDa is shown. CJD, Creutzfeldt-Jakob disease; sCJD, sporadic CJD; vCJD, variant CJD.</p></caption><graphic xlink:href="16-1948-F3"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We report a detailed comparison of the transmission properties of BSE and vCJD prions among humanized transgenic mice with different <italic>PRNP</italic> codon 129 genotypes. Because a high expression level of PrP in transgenic mice directly influences prion disease susceptibility and incubation time, these transgenic mice have an advantage over knock-in mice for evaluating these features in the different human PrP genotypes. In addition, the 3 mouse models used in our study have equivalent PrP expression levels, making them suitable for studying comparative susceptibilities across the different <italic>PRNP</italic> codon 129 genotypes.</p><p>In previous reports, we demonstrated that Met<sub>129</sub> homozygous individuals might be susceptible to a sheep or goat BSE agent to a higher degree than to cattle BSE and that these agents might transmit with molecular and neuropathological properties indistinguishable from those of vCJD (<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>). In this study, we wanted to extend these results to the other human <italic>PRNP</italic> genotypes: Met/Val<sub>129</sub> and Val/Val<sub>129</sub>. We gained a different perspective when several BSE isolates adapted to different species inoculated in TgVal<sub>129</sub> mice showed an apparent lack of transmission. In addition, almost all inoculated TgMet/Val<sub>129</sub> mice did not transmit BSE; this finding supports the interpretation by Wadsworth et al. that human PrP Val<sub>129</sub> severely restricts propagation of the BSE prion strain (<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>). </p><p>An unexpected result of this study was the finding that 1 BSE isolate from a goat (Ca-BSE/Go) was clinically transmitted to 1 of 10 TgMet/Val<sub>129</sub> mice and subclinically transmitted to TgVal<sub>129</sub> mice. This particular isolate is characterized by a high infectious titer (<xref rid="R35" ref-type="bibr"><italic>35</italic></xref>) that could explain the potential for this inoculum to overcome the restriction on BSE prions to propagate in TgVal<sub>129</sub> mice.</p><p>Although cattle BSE did not transmit to TgMet/Val<sub>129</sub> mice directly, adaptation of the BSE agent to human PrP Met<sub>129</sub> sequence and subsequent inoculation of the resultant vCJD prions to TgMet/Val<sub>129</sub> mice produced a 100% attack rate. However, we did not detect clinical prion disease, supporting a slower rate of vCJD conversion compared with that among TgMet<sub>129</sub> mice. This slow but potential conversion rate in TgMet/Val<sub>129</sub> mice correlates well with the single vCJD case of a human carrying the PrP Met/Val<sub>129</sub> genotype (<xref rid="R22" ref-type="bibr"><italic>22</italic></xref>) and with the description of subclinical secondary transmissions through human vCJD&#x02013;infected tissues (<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>&#x02013;<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>,<xref rid="R47" ref-type="bibr"><italic>47</italic></xref>).</p><p>TgVal<sub>129</sub> mice challenged with Hu-vCJD<sub>2</sub> did not produce detectable brain PrP<sup>res</sup> and clinical signs, in spite of the overexpression of HuPrP-Val<sub>129</sub> and the use of the more efficient intracerebral route of infection. However, subclinical infection in these TgVal<sub>129</sub> mice was demonstrated in BoPrP-Tg110 mice. These data suggest that PrP Val<sub>129</sub> could sustain a very slow and limited vCJD conversion rate that is consistent with the detection of PrP<sup>res</sup> in tonsils and appendixes of asymptomatic PrP Val<sub>129</sub> persons (<xref rid="R23" ref-type="bibr"><italic>23</italic></xref>&#x02013;<xref rid="R25" ref-type="bibr"><italic>25</italic></xref>). Previous studies of other transgenic mice expressing PrP Val<sub>129</sub> have also shown a low transmission efficiency of vCJD (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>,<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>).</p><p>The fluctuating subclinical transmissibility of both vCJD inocula in TgVal<sub>129</sub> mice (negative for Hu-vCJD<sub>1</sub> and positive for Hu-vCJD<sub>2</sub>) might be caused by differences in prion titer between inocula. This assessment was strengthened after the transmission of both vCJDs to TgMet<sub>129</sub> mice, in which a shorter incubation period was observed in animals inoculated with Hu-vCJD<sub>2</sub>. A certain variability in subclinical transmissibility and incubation time between different vCJD isolates is not uncommon, as has been previously reported (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>,<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>), suggesting that a Val<sub>129</sub> transmission barrier can only be overcome with highly infectious vCJD isolates.</p><p>The dramatic changes in the susceptibility of TgVal<sub>129</sub> mice (<xref ref-type="table" rid="T3">Table 3</xref>) challenged with vCJD isolates first passaged in TgMet<sub>129</sub> mice suggest an apparent increase in titer of both vCJD prion isolates; however, adaptation of the inocula to the new host mouse cannot be disregarded as being partly responsible for this increased susceptibility. We observed a 100% infection rate, but without clinical signs of prion disease. We observed similar transmission features when we passaged vCJD in TgMet/Val<sub>129</sub> mice. In addition, the apparent PrPVal<sub>129</sub> restricted propagation of cattle BSE and BSE from other species was completely abolished after its adaptation to human PrPMet<sub>129</sub>.</p><p>Although PrP overexpression and the inoculation route can affect transmission efficiency, our results and those previously reported in both overexpressing and knock-in transgenic mice (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>,<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>) suggest that the Val<sub>129</sub> PrP variant could sustain a very slow and limited vCJD conversion rate, and is unable to completely prevent vCJD transmission. Biochemical and neuropathological features of vCJD transmission to TgVal<sub>129</sub> mice showed substantial differences compared to TgMet<sub>129</sub> or TgMet/Val<sub>129</sub> mice. Similar to previous reports (<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>,<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>,<xref rid="R48" ref-type="bibr"><italic>48</italic></xref>), a type 5 PrP<sup>Sc</sup> associated with very weak and diffuse PrP plaques without a florid morphology was the hallmark among these mice. In addition, our demonstration of previously unreported type 5 PrP<sup>Sc</sup> in brain samples of vCJD-challenged knock-in Ki-Hu129V/V mice (<xref rid="R30" ref-type="bibr"><italic>30</italic></xref>) establishes that the evolution of type 5 PrP<sup>Sc</sup> associated with the transmission of vCJD prions to the Val<sub>129</sub> genotype is not an artifact of PrP overexpression. This finding further reinforces the specific biochemical features of vCJD when transmitted to the human-PrP Val<sub>129</sub> sequence.</p><p>Extrapolation of results from prion transmission studies based on transgenic mice has to be done with caution, especially when human susceptibility to prions is analyzed. However, our results clearly indicate that PrPVal<sub>129</sub> individuals are highly resistant to transmission of cattle BSE or BSE passaged in other species. Also, PrPVal<sub>129</sub> individuals might be susceptible to infection with human-passaged BSE (vCJD) prions, and the propagated agents might transmit with molecular and neuropathological properties distinguishable from those of type 4 PrP<sup>res</sup>. Although the resultant type 5 PrP<sup>Sc</sup> shares the same fragment sizes as those of type 2 PrP<sup>Sc</sup>, the 2 PrP<sup>Sc</sup> types can be distinguished by the predominance of the diglycosylated glycoform associated with type 5 PrP<sup>Sc</sup>. Overall, our results indicate that human Val<sub>129</sub>-PrP polymorphic variant is a strong molecular protector against BSE zoonotic transmission but fails to prevent human-to-human vCJD transmission. Because potential late-onset vCJD cases could appear in the population (<xref rid="R49" ref-type="bibr"><italic>49</italic></xref>,<xref rid="R50" ref-type="bibr"><italic>50</italic></xref>) these findings underline the need for continued investigation of all forms of human prion disease.</p></sec><sec sec-type="supplementary-material"><title/><supplementary-material content-type="local-data" id="SD1"><caption><title>Technical Appendix</title><p>Transmission of Ca-BSE bovine spongiform encephalopathy&#x02013;derived isolates adapted in different human prion protein polymorphic variants to BoPrP-Tg110 mice and <bold>t</bold>ransmission of variant Creutzfeldt-Jakob disease and cattle, sheep, and goat BSE isolates to TgVal129 (8&#x000d7;) mice.</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="16-1948-Techapp-s1.pdf" xlink:type="simple" id="d35e1980" position="anchor"/></supplementary-material></sec></body><back><fn-group><fn fn-type="citation"><p><italic>Suggested citation for this article</italic>: Fern&#x000e1;ndez-Borges N, Espinosa JC, Mar&#x000ed;n-Moreno A, Aguilar-Calvo P, Asante EA, Kitamoto T, et al. Protective effect of val129-PrP against bovine spongiform encephalopathy but not variant Creutzfeldt-Jakob disease. Emerg Infect Dis. 2017 Sep [<italic>date cited</italic>]. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3201/eid2309.161948">https://doi.org/10.3201/eid2309.161948</ext-link></p></fn><fn id="FN1"><label>1</label><p>These authors contributed equally to this article.</p></fn></fn-group><ack><title>Acknowledgments</title><p>We thank Wilfred Goldmann for providing the goat-BSE material (gBSE-P12); Juan Piquer, Irene Prieto, Patricia Lorenzo, Ana Esteban, and Ana Villa for their technical assistance; and the staff of the Biosafety Level 3 animal facility and the Biosafety Office at the CISA-INIA (Valdeolmos-Madrid) for their excellent animal care and work.</p><p>This work was funded by the European Union projects CT-2006-36353 (GoatBSE), CT-2009-222887 (Priority), and 219235 ERANET EMIDA (GOAT-TSE-FREE); the UK Food Standards Agency grant M03043; the Alliance BioSecure Foundation grant FABS201403; and the Spanish Plan Nacional de I+D+I RTA2012-00004 and AGL2015-71764-REDT projects.</p></ack><bio id="d35e2005"><p>Dr. Fern&#x000e1;ndez-Borges is a research scientist in the Prion Group at Centro de Investigaci&#x000f3;n en Sanidad Animal&#x02013;Instituto Nacional de Investigaci&#x000f3;n y Tecnolog&#x000ed;a Agraria y Alimentaria, Madrid, Spain. Her research interests include prion strain characterization and evolution and the pathogenesis of prion diseases and their effects on human and animal health.</p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="journal"><string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sidle</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Meads</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hill</surname>
<given-names>AF</given-names></string-name>. <article-title>Molecular analysis of prion strain variation and the aetiology of &#x02018;new variant&#x02019; CJD.</article-title>
<source>Nature</source>. <year>1996</year>;<volume>383</volume>:<fpage>685</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/383685a0</pub-id><pub-id pub-id-type="pmid">8878476</pub-id></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name><surname>Hill</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Desbruslais</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sidle</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Gowland</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>The same prion strain causes vCJD and BSE.</article-title>
<source>Nature</source>. <year>1997</year>;<volume>389</volume>:<fpage>448</fpage>&#x02013;<lpage>50, 526</lpage>. <pub-id pub-id-type="doi">10.1038/38925</pub-id><pub-id pub-id-type="pmid">9333232</pub-id></mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="journal"><string-name><surname>Bruce</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Will</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>McConnell</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Drummond</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Suttie</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Transmissions to mice indicate that &#x02018;new variant&#x02019; CJD is caused by the BSE agent.</article-title>
<source>Nature</source>. <year>1997</year>;<volume>389</volume>:<fpage>498</fpage>&#x02013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1038/39057</pub-id><pub-id pub-id-type="pmid">9333239</pub-id></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name><surname>Llewelyn</surname>
<given-names>CA</given-names></string-name>, <string-name><surname>Hewitt</surname>
<given-names>PE</given-names></string-name>, <string-name><surname>Knight</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Amar</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Cousens</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mackenzie</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal>
<article-title>Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.</article-title>
<source>Lancet</source>. <year>2004</year>;<volume>363</volume>:<fpage>417</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)15486-X</pub-id><pub-id pub-id-type="pmid">14962520</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="journal"><string-name><surname>Peden</surname>
<given-names>AH</given-names></string-name>, <string-name><surname>Head</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Ritchie</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>. <article-title>Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.</article-title>
<source>Lancet</source>. <year>2004</year>;<volume>364</volume>:<fpage>527</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16811-6</pub-id><pub-id pub-id-type="pmid">15302196</pub-id></mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name><surname>Wroe</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Pal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Siddique</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hyare</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Macfarlane</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.</article-title>
<source>Lancet</source>. <year>2006</year>;<volume>368</volume>:<fpage>2061</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(06)69835-8</pub-id><pub-id pub-id-type="pmid">17161728</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name><surname>Peden</surname>
<given-names>A</given-names></string-name>, <string-name><surname>McCardle</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Head</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Love</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Cousens</surname>
<given-names>SN</given-names></string-name>, <etal>et al.</etal>
<article-title>Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.</article-title>
<source>Haemophilia</source>. <year>2010</year>;<volume>16</volume>:<fpage>296</fpage>&#x02013;<lpage>304</lpage> . <pub-id pub-id-type="doi">10.1111/j.1365-2516.2009.02181.x</pub-id><pub-id pub-id-type="pmid">20070383</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="journal"><string-name><surname>Prusiner</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>DeArmond</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>FE</given-names></string-name>. <article-title>Prion protein biology.</article-title>
<source>Cell</source>. <year>1998</year>;<volume>93</volume>:<fpage>337</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81163-0</pub-id><pub-id pub-id-type="pmid">9590169</pub-id></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="journal"><string-name><surname>Prusiner</surname>
<given-names>SB</given-names></string-name>. <article-title>Prions.</article-title>
<source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>:<fpage>13363</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.23.13363</pub-id><pub-id pub-id-type="pmid">9811807</pub-id></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>. <article-title>Prion diseases of humans and animals: their causes and molecular basis.</article-title>
<source>Annu Rev Neurosci</source>. <year>2001</year>;<volume>24</volume>:<fpage>519</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.519</pub-id><pub-id pub-id-type="pmid">11283320</pub-id></mixed-citation></ref><ref id="R11"><label>11. </label><mixed-citation publication-type="journal"><string-name><surname>Will</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Zeidler</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Cousens</surname>
<given-names>SN</given-names></string-name>, <string-name><surname>Estibeiro</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Alperovitch</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>A new variant of Creutzfeldt-Jakob disease in the UK.</article-title>
<source>Lancet</source>. <year>1996</year>;<volume>347</volume>:<fpage>921</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(96)91412-9</pub-id><pub-id pub-id-type="pmid">8598754</pub-id></mixed-citation></ref><ref id="R12"><label>12. </label><mixed-citation publication-type="journal"><string-name><surname>Parchi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Castellani</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Capellari</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ghetti</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Young</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>SG</given-names></string-name>, <etal>et al.</etal>
<article-title>Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease.</article-title>
<source>Ann Neurol</source>. <year>1996</year>;<volume>39</volume>:<fpage>767</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/ana.410390613</pub-id><pub-id pub-id-type="pmid">8651649</pub-id></mixed-citation></ref><ref id="R13"><label>13. </label><mixed-citation publication-type="journal"><string-name><surname>Hill</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wadsworth</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Sidle</surname>
<given-names>KC</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Budka</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Molecular classification of sporadic Creutzfeldt-Jakob disease.</article-title>
<source>Brain</source>. <year>2003</year>;<volume>126</volume>:<fpage>1333</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awg125</pub-id><pub-id pub-id-type="pmid">12764055</pub-id></mixed-citation></ref><ref id="R14"><label>14. </label><mixed-citation publication-type="journal"><string-name><surname>Torres</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Espinosa</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Aguilar-Calvo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Herva</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Rela&#x000f1;o-Gin&#x000e9;s</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Villa-Diaz</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Elements modulating the prion species barrier and its passage consequences.</article-title>
<source>PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e89722</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0089722</pub-id><pub-id pub-id-type="pmid">24608126</pub-id></mixed-citation></ref><ref id="R15"><label>15. </label><mixed-citation publication-type="other"><string-name><surname>Wadsworth</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>. Update on human prion disease. Biochim Biophys Acta. <year>2007</year>;1772:598&#x02013;609. </mixed-citation></ref><ref id="R16"><label>16. </label><mixed-citation publication-type="journal"><string-name><surname>Palmer</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Dryden</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>. <article-title>Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.</article-title>
<source>Nature</source>. <year>1991</year>;<volume>352</volume>:<fpage>340</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/352340a0</pub-id><pub-id pub-id-type="pmid">1677164</pub-id></mixed-citation></ref><ref id="R17"><label>17. </label><mixed-citation publication-type="journal"><string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Palmer</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Dryden</surname>
<given-names>AJ</given-names></string-name>. <article-title>Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease.</article-title>
<source>Lancet</source>. <year>1991</year>;<volume>337</volume>:<fpage>1441</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)93128-V</pub-id><pub-id pub-id-type="pmid">1675319</pub-id></mixed-citation></ref><ref id="R18"><label>18. </label><mixed-citation publication-type="journal"><string-name><surname>Mead</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Stumpf</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Whitfield</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Beck</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Poulter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Campbell</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics.</article-title>
<source>Science</source>. <year>2003</year>;<volume>300</volume>:<fpage>640</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1126/science.1083320</pub-id><pub-id pub-id-type="pmid">12690204</pub-id></mixed-citation></ref><ref id="R19"><label>19. </label><mixed-citation publication-type="journal"><string-name><surname>Baker</surname>
<given-names>HE</given-names></string-name>, <string-name><surname>Poulter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Crow</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Frith</surname>
<given-names>CD</given-names></string-name>, <string-name><surname>Lofthouse</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ridley</surname>
<given-names>RM</given-names></string-name>, <etal>et al.</etal>
<article-title>Aminoacid polymorphism in human prion protein and age at death in inherited prion disease.</article-title>
<source>Lancet</source>. <year>1991</year>;<volume>337</volume>:<fpage>1286</fpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)92953-Y</pub-id><pub-id pub-id-type="pmid">1674080</pub-id></mixed-citation></ref><ref id="R20"><label>20. </label><mixed-citation publication-type="journal"><string-name><surname>Poulter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>HF</given-names></string-name>, <string-name><surname>Frith</surname>
<given-names>CD</given-names></string-name>, <string-name><surname>Leach</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lofthouse</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ridley</surname>
<given-names>RM</given-names></string-name>, <etal>et al.</etal>
<article-title>Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies.</article-title>
<source>Brain</source>. <year>1992</year>;<volume>115</volume>:<fpage>675</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/brain/115.3.675</pub-id><pub-id pub-id-type="pmid">1352724</pub-id></mixed-citation></ref><ref id="R21"><label>21. </label><mixed-citation publication-type="journal"><string-name><surname>Will</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Zeidler</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stewart</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Macleod</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Cousens</surname>
<given-names>SN</given-names></string-name>, <etal>et al.</etal>
<article-title>Diagnosis of new variant Creutzfeldt-Jakob disease.</article-title>
<source>Ann Neurol</source>. <year>2000</year>;<volume>47</volume>:<fpage>575</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/1531-8249(200005)47:5&#x0003c;575::AID-ANA4&#x0003e;3.0.CO;2-W</pub-id><pub-id pub-id-type="pmid">10805327</pub-id></mixed-citation></ref><ref id="R22"><label>22. </label><mixed-citation publication-type="journal"><string-name><surname>Bishop</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Diack</surname>
<given-names>AB</given-names></string-name>, <string-name><surname>Ritchie</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Will</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Manson</surname>
<given-names>JC</given-names></string-name>. <article-title>Prion infectivity in the spleen of a PRNP heterozygous individual with subclinical variant Creutzfeldt-Jakob disease.</article-title>
<source>Brain</source>. <year>2013</year>;<volume>136</volume>:<fpage>1139</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awt032</pub-id><pub-id pub-id-type="pmid">23449776</pub-id></mixed-citation></ref><ref id="R23"><label>23. </label><mixed-citation publication-type="journal"><string-name><surname>Hilton</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Ghani</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Conyers</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Edwards</surname>
<given-names>P</given-names></string-name>, <string-name><surname>McCardle</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ritchie</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Prevalence of lymphoreticular prion protein accumulation in UK tissue samples.</article-title>
<source>J Pathol</source>. <year>2004</year>;<volume>203</volume>:<fpage>733</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/path.1580</pub-id><pub-id pub-id-type="pmid">15221931</pub-id></mixed-citation></ref><ref id="R24"><label>24. </label><mixed-citation publication-type="journal"><string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Bishop</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Connolly</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hegazy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lowrie</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Le Grice</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study.</article-title>
<source>BMJ</source>. <year>2006</year>;<volume>332</volume>:<fpage>1186</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.38804.511644.55</pub-id><pub-id pub-id-type="pmid">16606639</pub-id></mixed-citation></ref><ref id="R25"><label>25. </label><mixed-citation publication-type="journal"><string-name><surname>Gill</surname>
<given-names>ON</given-names></string-name>, <string-name><surname>Spencer</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Richard-Loendt</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Dabaghian</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Boyes</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal>
<article-title>Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey.</article-title>
<source>BMJ</source>. <year>2013</year>;<volume>347</volume>(<issue>oct15 5</issue>):<fpage>f5675</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.f5675</pub-id><pub-id pub-id-type="pmid">24129059</pub-id></mixed-citation></ref><ref id="R26"><label>26. </label><mixed-citation publication-type="journal"><string-name><surname>Asante</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Linehan</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Desbruslais</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gowland</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Wood</surname>
<given-names>AL</given-names></string-name>, <etal>et al.</etal>
<article-title>BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein.</article-title>
<source>EMBO J</source>. <year>2002</year>;<volume>21</volume>:<fpage>6358</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1093/emboj/cdf653</pub-id><pub-id pub-id-type="pmid">12456643</pub-id></mixed-citation></ref><ref id="R27"><label>27. </label><mixed-citation publication-type="journal"><string-name><surname>Wadsworth</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Asante</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Desbruslais</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Linehan</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gowland</surname>
<given-names>I</given-names></string-name>, <etal>et al.</etal>
<article-title>Human prion protein with valine 129 prevents expression of variant CJD phenotype.</article-title>
<source>Science</source>. <year>2004</year>;<volume>306</volume>:<fpage>1793</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.1103932</pub-id><pub-id pub-id-type="pmid">15539564</pub-id></mixed-citation></ref><ref id="R28"><label>28. </label><mixed-citation publication-type="journal"><string-name><surname>Asante</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Linehan</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Gowland</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fox</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice.</article-title>
<source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>:<fpage>10759</fpage>&#x02013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0604292103</pub-id><pub-id pub-id-type="pmid">16809423</pub-id></mixed-citation></ref><ref id="R29"><label>29. </label><mixed-citation publication-type="journal"><string-name><surname>Bishop</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Hart</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Aitchison</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Baybutt</surname>
<given-names>HN</given-names></string-name>, <string-name><surname>Plinston</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Thomson</surname>
<given-names>V</given-names></string-name>, <etal>et al.</etal>
<article-title>Predicting susceptibility and incubation time of human-to-human transmission of vCJD.</article-title>
<source>Lancet Neurol</source>. <year>2006</year>;<volume>5</volume>:<fpage>393</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(06)70413-6</pub-id><pub-id pub-id-type="pmid">16632309</pub-id></mixed-citation></ref><ref id="R30"><label>30. </label><mixed-citation publication-type="journal"><string-name><surname>Takeuchi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kobayashi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ironside</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Mohri</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kitamoto</surname>
<given-names>T</given-names></string-name>. <article-title>Characterization of variant Creutzfeldt-Jakob disease prions in prion protein-humanized mice carrying distinct codon 129 genotypes.</article-title>
<source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>:<fpage>21659</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.470328</pub-id><pub-id pub-id-type="pmid">23792955</pub-id></mixed-citation></ref><ref id="R31"><label>31. </label><mixed-citation publication-type="journal"><string-name><surname>Padilla</surname>
<given-names>D</given-names></string-name>, <string-name><surname>B&#x000e9;ringue</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Espinosa</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Andreoletti</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Jaumain</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Reine</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice.</article-title>
<source>PLoS Pathog</source>. <year>2011</year>;<volume>7</volume>:<fpage>e1001319</fpage> . <pub-id pub-id-type="doi">10.1371/journal.ppat.1001319</pub-id><pub-id pub-id-type="pmid">21445238</pub-id></mixed-citation></ref><ref id="R32"><label>32. </label><mixed-citation publication-type="journal"><string-name><surname>Espinosa</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Herva</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Andr&#x000e9;oletti</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Padilla</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lacroux</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Cassard</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Transgenic mice expressing porcine prion protein resistant to classical scrapie but susceptible to sheep bovine spongiform encephalopathy and atypical scrapie.</article-title>
<source>Emerg Infect Dis</source>. <year>2009</year>;<volume>15</volume>:<fpage>1214</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.3201/eid1508.081218</pub-id><pub-id pub-id-type="pmid">19751582</pub-id></mixed-citation></ref><ref id="R33"><label>33. </label><mixed-citation publication-type="journal"><string-name><surname>Castilla</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guti&#x000e9;rrez Ad&#x000e1;n</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Brun</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pintado</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ram&#x000ed;rez</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Parra</surname>
<given-names>B</given-names></string-name>, <etal>et al.</etal>
<article-title>Early detection of PrPres in BSE-infected bovine PrP transgenic mice.</article-title>
<source>Arch Virol</source>. <year>2003</year>;<volume>148</volume>:<fpage>677</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-002-0958-4</pub-id><pub-id pub-id-type="pmid">12664293</pub-id></mixed-citation></ref><ref id="R34"><label>34. </label><mixed-citation publication-type="journal"><string-name><surname>Castilla</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guti&#x000e9;rrez-Ad&#x000e1;n</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Brun</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Doyle</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pintado</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ram&#x000ed;rez</surname>
<given-names>MA</given-names></string-name>, <etal>et al.</etal>
<article-title>Subclinical bovine spongiform encephalopathy infection in transgenic mice expressing porcine prion protein.</article-title>
<source>J Neurosci</source>. <year>2004</year>;<volume>24</volume>:<fpage>5063</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5400-03.2004</pub-id><pub-id pub-id-type="pmid">15163699</pub-id></mixed-citation></ref><ref id="R35"><label>35. </label><mixed-citation publication-type="journal"><string-name><surname>Aguilar-Calvo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Fast</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tauscher</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Espinosa</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Groschup</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Nadeem</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Effect of Q211 and K222 PRNP polymorphic variants in the susceptibility of goats to oral infection with goat bovine spongiform encephalopathy.</article-title>
<source>J Infect Dis</source>. <year>2015</year>;<volume>212</volume>:<fpage>664</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv112</pub-id><pub-id pub-id-type="pmid">25722297</pub-id></mixed-citation></ref><ref id="R36"><label>36. </label><mixed-citation publication-type="journal"><string-name><surname>Foster</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Hope</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Fraser</surname>
<given-names>H</given-names></string-name>. <article-title>Transmission of bovine spongiform encephalopathy to sheep and goats.</article-title>
<source>Vet Rec</source>. <year>1993</year>;<volume>133</volume>:<fpage>339</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1136/vr.133.14.339</pub-id><pub-id pub-id-type="pmid">8236676</pub-id></mixed-citation></ref><ref id="R37"><label>37. </label><mixed-citation publication-type="journal"><string-name><surname>Goldmann</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Martin</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Foster</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Hughes</surname>
<given-names>K</given-names></string-name>, <etal>et al.</etal>
<article-title>Novel polymorphisms in the caprine PrP gene: a codon 142 mutation associated with scrapie incubation period.</article-title>
<source>J Gen Virol</source>. <year>1996</year>;<volume>77</volume>:<fpage>2885</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-77-11-2885</pub-id><pub-id pub-id-type="pmid">8922485</pub-id></mixed-citation></ref><ref id="R38"><label>38. </label><mixed-citation publication-type="journal"><string-name><surname>Eloit</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Adjou</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Coulpier</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fontaine</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Hamel</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lilin</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>BSE agent signatures in a goat.</article-title>
<source>Vet Rec</source>. <year>2005</year>;<volume>156</volume>:<fpage>523</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/vr.156.16.523-b</pub-id><pub-id pub-id-type="pmid">15833975</pub-id></mixed-citation></ref><ref id="R39"><label>39. </label><mixed-citation publication-type="journal"><string-name><surname>Cooper</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Ladhani</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Minor</surname>
<given-names>PD</given-names></string-name>. <article-title>Reference materials for the evaluation of pre-mortem variant Creutzfeldt-Jakob disease diagnostic assays.</article-title>
<source>Vox Sang</source>. <year>2007</year>;<volume>92</volume>:<fpage>302</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">17456154</pub-id></mixed-citation></ref><ref id="R40"><label>40. </label><mixed-citation publication-type="journal"><string-name><surname>Cassard</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Torres</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Lacroux</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Douet</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Benestad</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Lantier</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Evidence for zoonotic potential of ovine scrapie prions.</article-title>
<source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>5821</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms6821</pub-id><pub-id pub-id-type="pmid">25510416</pub-id></mixed-citation></ref><ref id="R41"><label>41. </label><mixed-citation publication-type="journal"><string-name><surname>Notari</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Xiao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Espinosa</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Cohen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Qing</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Aguilar-Calvo</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal>
<article-title>Transmission characteristics of variably protease-sensitive prionopathy.</article-title>
<source>Emerg Infect Dis</source>. <year>2014</year>;<volume>20</volume>:<fpage>2006</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.3201/eid2012.140548</pub-id><pub-id pub-id-type="pmid">25418590</pub-id></mixed-citation></ref><ref id="R42"><label>42. </label><mixed-citation publication-type="journal"><string-name><surname>F&#x000e9;raudet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Morel</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Simon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Volland</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Frobert</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Cr&#x000e9;minon</surname>
<given-names>C</given-names></string-name>, <etal>et al.</etal>
<article-title>Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.</article-title>
<source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>:<fpage>11247</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M407006200</pub-id><pub-id pub-id-type="pmid">15618225</pub-id></mixed-citation></ref><ref id="R43"><label>43. </label><mixed-citation publication-type="journal"><string-name><surname>Andr&#x000e9;oletti</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Berthon</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Levavasseur</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Marc</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lantier</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Monks</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Phenotyping of protein-prion (PrPsc)-accumulating cells in lymphoid and neural tissues of naturally scrapie-affected sheep by double-labeling immunohistochemistry.</article-title>
<source>J Histochem Cytochem</source>. <year>2002</year>;<volume>50</volume>:<fpage>1357</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1177/002215540205001009</pub-id><pub-id pub-id-type="pmid">12364569</pub-id></mixed-citation></ref><ref id="R44"><label>44. </label><mixed-citation publication-type="journal"><string-name><surname>Fraser</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Dickinson</surname>
<given-names>AG</given-names></string-name>. <article-title>The sequential development of the brain lesion of scrapie in three strains of mice.</article-title>
<source>J Comp Pathol</source>. <year>1968</year>;<volume>78</volume>:<fpage>301</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/0021-9975(68)90006-6</pub-id><pub-id pub-id-type="pmid">4970192</pub-id></mixed-citation></ref><ref id="R45"><label>45. </label><mixed-citation publication-type="journal"><string-name><surname>Andr&#x000e9;oletti</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Simon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lacroux</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Morel</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tabouret</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Chabert</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>PrPSc accumulation in myocytes from sheep incubating natural scrapie.</article-title>
<source>Nat Med</source>. <year>2004</year>;<volume>10</volume>:<fpage>591</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nm1055</pub-id><pub-id pub-id-type="pmid">15156203</pub-id></mixed-citation></ref><ref id="R46"><label>46. </label><mixed-citation publication-type="journal"><string-name><surname>Wadsworth</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Powell</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Beck</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Joiner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Linehan</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Brandner</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>Molecular diagnosis of human prion disease.</article-title>
<source>Methods Mol Biol</source>. <year>2008</year>;<volume>459</volume>:<fpage>197</fpage>&#x02013;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-59745-234-2_14</pub-id><pub-id pub-id-type="pmid">18576157</pub-id></mixed-citation></ref><ref id="R47"><label>47. </label><mixed-citation publication-type="journal"><string-name><surname>Vidal</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Fern&#x000e1;ndez-Borges</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pintado</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ord&#x000f3;&#x000f1;ez</surname>
<given-names>M</given-names></string-name>, <string-name><surname>M&#x000e1;rquez</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fondevila</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Bovine spongiform encephalopathy induces misfolding of alleged prion-resistant species cellular prion protein without altering its pathobiological features.</article-title>
<source>J Neurosci</source>. <year>2013</year>;<volume>33</volume>:<fpage>7778</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0244-13.2013</pub-id><pub-id pub-id-type="pmid">23637170</pub-id></mixed-citation></ref><ref id="R48"><label>48. </label><mixed-citation publication-type="journal"><string-name><surname>de Marco</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Linehan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gill</surname>
<given-names>ON</given-names></string-name>, <string-name><surname>Clewley</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Brandner</surname>
<given-names>S</given-names></string-name>. <article-title>Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain.</article-title>
<source>J Pathol</source>. <year>2010</year>;<volume>222</volume>:<fpage>380</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/path.2767</pub-id><pub-id pub-id-type="pmid">20922767</pub-id></mixed-citation></ref><ref id="R49"><label>49. </label><mixed-citation publication-type="journal"><string-name><surname>Collinge</surname>
<given-names>J</given-names></string-name>. <article-title>Medicine. Prion strain mutation and selection.</article-title>
<source>Science</source>. <year>2010</year>;<volume>328</volume>:<fpage>1111</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1126/science.1190815</pub-id><pub-id pub-id-type="pmid">20508117</pub-id></mixed-citation></ref><ref id="R50"><label>50. </label><mixed-citation publication-type="journal"><string-name><surname>Douet</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Zafar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Perret-Liaudet</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lacroux</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lugan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Aron</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal>
<article-title>Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease.</article-title>
<source>Emerg Infect Dis</source>. <year>2014</year>;<volume>20</volume>:<fpage>114</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3201/eid2001.130353</pub-id><pub-id pub-id-type="pmid">24377668</pub-id></mixed-citation></ref></ref-list></back></article>